TLSI (TriSalus Life Sciences) FCF Yield % : -27.55 (As of Apr. 05, 2025)

View and export this data going back to 2023. Start your Free Trial

What is TriSalus Life Sciences FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, TriSalus Life Sciences's Trailing 12-Month Free Cash Flow is $-44.98 Mil, and Market Cap is $162.97 Mil. Therefore, TriSalus Life Sciences's FCF Yield % for today is -27.55%.

The historical rank and industry rank for TriSalus Life Sciences's FCF Yield % or its related term are showing as below:

TLSI' s FCF Yield % Range Over the Past 10 Years
Min: -87.27 Med: -33.93 Max: -6.28
Current: -27.55

During the past 4 years, the highest FCF Yield % of TriSalus Life Sciences was -6.28%. The lowest was -87.27%. And the median was -33.93%.

TLSI's FCF Yield % is ranked worse than
81.22% of 868 companies
in the Medical Devices & Instruments industry
Industry Median: -1.98 vs TLSI: -27.55

TriSalus Life Sciences's FCF Margin % for the quarter that ended in Sep. 2024 was -149.90%.

TriSalus Life Sciences FCF Yield % Historical Data

The historical data trend for TriSalus Life Sciences's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TriSalus Life Sciences FCF Yield % Chart

TriSalus Life Sciences Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

FCF Yield %

-22.92

TriSalus Life Sciences Quarterly Data
	Dec21	Mar22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Yield %	Get a 7-Day Free Trial							-17.11	-16.76	-35.97	-31.37	-

Competitive Comparison of TriSalus Life Sciences's FCF Yield %

For the Medical Devices subindustry, TriSalus Life Sciences's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TriSalus Life Sciences's FCF Yield % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's FCF Yield % distribution charts can be found below:

* The bar in red indicates where TriSalus Life Sciences's FCF Yield % falls into.

Save Embed

;

Save Embed

;

TriSalus Life Sciences FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

TriSalus Life Sciences's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-51.166	/	223.18985
	=	-22.92%

TriSalus Life Sciences's annualized FCF Yield % for the quarter that ended in Sep. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-11.016	*	4	/	140.4667
	=	-31.37%

TriSalus Life Sciences FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

TriSalus Life Sciences FCF Yield % Related Terms

Thank you for viewing the detailed overview of TriSalus Life Sciences's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

TriSalus Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TriSalus Life Sciences Inc (NAS:TLSI) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

6272 W. 91st Avenue, Westminster, CO, USA, 80031

Website

https://www.trisaluslifesci.com

TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines?Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

Executives

Mary T Szela	director, officer: CEO and President	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Sean Murphy	director, officer: Chief Financial Officer	C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703
Equity Ab Frankenius	10 percent owner	BOX 984, BORAS V7 SE-501 10
Arjun Jj Desai	director	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Mats Wahlstrom	director, 10 percent owner	500 GOLDEN RIDGE ROAD, SUITE 100, GOLDEN CO 80401
Bryan F. Cox	officer: Chief Scientific & Manufact.	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
George Kelly Martin	director	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Jodi Devlin	officer: President, Therapeutics	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Kerry R Hicks	director	C/O HEALTHGRADES.COM, 44 UNION BLVD SUITE 600, LAKEOOD CO 80228
James Alecxih	officer: President, Device Technology	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Anil K. Singhal	director	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Steven C Katz	officer: Chief Medical Officer	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Von Eschenbach Andrew C.	director	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Richard Marshak	officer: Sr.VP, Corp. Dev. & Strategy	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Jennifer Stevens	officer: Chief Regulatory Officer	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031